Bayer looks to Xarelto to take it past the ¥200bn mark in Japan
This article was originally published in Scrip
Executive Summary
Bayer Yakuhin, Bayer's pharmaceutical subsidiary in Japan, is confident that its sales will surpass the ¥200 billion ($2.43 billion) level next year, driven by new launches and despite this month's industry-wide reimbursement price cut.
You may also be interested in...
Quick Listen: Scrip’s Five Must-Know Things
Join us for a brief audio tour around the past week's major global biopharma industry developments, in this podcast version of Scrip's Five Must-Know Things.
PMDA Eyes More Japan-First Approvals In Access Push
Highlighting progress it has made over the past few years, Japan’s regulatory agency says it wants to raise even further the number of “Japan-first” approvals, as part of its stated mission to get safe and effective new drugs to patients more quickly.
Quick Listen: Scrip’s Five Must-Know Things
Join us for a brief audio tour around the past week's key developments in the global biopharma industry, in this podcast version of Scrip's Five Must-Know Things.
Need a specific report? 1000+ reports available
Buy Reports